| 摘要: |
| ［摘要］ 乳腺癌为女性高发癌症，其治疗模式为个体化综合治疗。诊治指南虽然很多，治疗也越来越规范，但仍存在争议。Ⅱa、Ⅱb期患者分期较早，治愈率高，需积极研究。放疗中很多争议集中在Ⅱa、Ⅱb期中T1-2，转移淋巴结1～3枚，无远处转移者（M0）在很多文献中习惯性称为“中度复发风险者”。结合中国抗癌协会乳腺癌诊治指南与规范、美国国立综合癌症网络指南（NCCN指南）、欧洲肿瘤内科学会指南（ESMO指南）等权威指南可了解这类患者治疗现状、争议及新进展，放疗科医师应更重视放疗中的争议。 |
| 关键词: 乳腺癌 化疗 内分泌治疗 靶向治疗 放疗 |
| DOI：10.3969/j.issn.1674-3806.2017.09.30 |
| 分类号:R 737.9 |
| 基金项目: |
|
| The current status of treatment for breast cancer in stage Ⅱa and Ⅱb and the controversy over radiotherapy |
|
QIN Heng, CHEN Long
|
|
The Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China
|
| Abstract: |
| ［Abstract］ Breast cancer is a high incidence of malignant tumors in women and its treatment mode is individualized and comprehensive. Although there are many related guidelines and more and more standardized regimens for the treatment, some therapies are still controversy. Ⅱa and Ⅱb stages are the early stage of breast cancer, in which the curative rate is high. Many controversies of radiotherapies focus on T1, T2, with 1～3 metastatic lymph nodes or non-metastasis in the patients, which are usually called “recurrence of moderate risk” in a myriad of literature reviews. Combining the treatment guidelines and norms of breast cancer of Chinese Anti-Cancer Association, with NCCN and ESMO guidelines, is helpful to understand the current status of treatment for breast cancer, and some therapeutic controversies on which radiation therapist should focus. |
| Key words: Breast cancer Chemotherapy Endocrine therapy Targeted therapy Radiotherapy |
